Eli Lilly's Gene Editing Drug Shows Significant Progress
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: Fool
- Weight Loss Market Growth: Eli Lilly's weight-loss drug Zepbound has become a best-seller, and the recently approved oral weight-loss pill Foundayo is also performing well, showcasing the company's strong competitive position in the rapidly growing weight-loss drug market.
- Gene Editing Potential: Eli Lilly's clinical trial results for VERVE-102 indicate that a one-time infusion can significantly lower LDL cholesterol with durable effects, potentially offering a revolutionary treatment option for high-risk cardiovascular patients and further solidifying its position in the gene editing space.
- Market Competition Landscape: While CRISPR Therapeutics' CTX310 also aims to reduce LDL and triglycerides, both target different patient populations and have distinct mechanisms, suggesting that the gene editing market could accommodate multiple winners, with Eli Lilly's entry posing a threat to smaller gene editing firms.
- Investment Choice Analysis: As an established pharmaceutical company, Eli Lilly offers stable revenue and profits, with its exploration in gene editing providing a relatively safe option for investors, whereas CRISPR Therapeutics presents a higher-risk, higher-reward investment opportunity suitable for those with a greater risk tolerance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1112.000
Low
950.00
Averages
1192
High
1500
Current: 1112.000
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Continues Growth, Surpasses $1 Trillion Market Value
- Weight Loss Market Potential: Eli Lilly's weight loss drugs, Zepbound and oral GLP-1 medication Foundayo, are experiencing rapid sales growth, particularly after Foundayo's approval for chronic weight management, with 80% of prescriptions coming from new GLP-1 users, indicating significant market potential and likely enhancing the company's leadership in this sector.
- Pipeline Diversification Investment: Eli Lilly is investing billions through acquisitions and licensing agreements to diversify its product lineup, particularly in oncology and neuroscience, with the acquisition of Morphic Holdings' MORF-057 oral medication for inflammatory bowel diseases poised to capture a significant market share, thereby reducing reliance on diabetes and obesity drugs.
- Dividend Growth Appeal: Although Eli Lilly's dividend yield is around 0.6%, the company has achieved a remarkable 239% increase in dividends over the past decade, showcasing its potential for healthy dividend growth, which attracts income-seeking investors and enhances its investment appeal.
- Strengthening Market Leadership: Eli Lilly's strong position in the weight loss market, combined with robust pipeline investments and ongoing revenue and earnings growth, positions the company to continue leading the industry over the next decade, making it a focal point for investors.
See More
Eli Lilly's Stock Soars 40%: Key Growth Drivers
- Weight Loss Market Potential: Eli Lilly's weight loss drug Zepbound (tirzepatide) is experiencing rapid sales growth, and the newly approved oral GLP-1 medication Foundayo is attracting 80% new patients, indicating significant untapped potential in this sector, which is expected to further solidify its market leadership.
- Pipeline Diversification Investment: Eli Lilly has invested billions through acquisitions and licensing agreements to expand its product lineup across multiple therapeutic areas, including oncology and neuroscience, aiming to reduce reliance on diabetes and obesity drugs and enhance future revenue streams.
- Strong Dividend Growth: Although Eli Lilly's dividend yield is around 0.6%, the company has seen a 239% increase in dividends over the past decade, showcasing its potential for healthy dividend growth, which appeals to income-seeking investors.
- Market Value Milestone: Eli Lilly has become the first healthcare company to reach a market value of $1 trillion, with a 40% stock price increase over the past 12 months, reflecting its strong performance among peers and confidence in future growth.
See More
Vertex and Eli Lilly's Market Competition in Pain Management
- Vertex Drug Approval: Vertex Pharmaceuticals' Journavx has become the first FDA-approved non-opioid pain signal inhibitor, marking a significant breakthrough in acute pain management, with expected sales growth over the coming years that will help reduce reliance on cystic fibrosis drugs.
- Eli Lilly Acquisitions: Last year, Eli Lilly acquired SiteOne Therapeutics for up to $1 billion, gaining the non-opioid chronic pain treatment STC-004, and recently announced the acquisition of 4E Therapeutics, further enhancing its competitive position in the pain management market.
- Market Potential: Vertex estimates that there are 80 million acute pain patients in North America and Europe, providing both Vertex and Eli Lilly opportunities to profit in this market; although Vertex currently leads, Eli Lilly's R&D progress could shift the competitive landscape.
- Strong Financial Performance: Despite Vertex's underperformance over the past 12 months, it expects to generate at least $500 million in revenue this year from Journavx and gene-editing drug Casgevy, indicating potential in new drug launches, while Eli Lilly is also viewed as a strong investment due to its robust pipeline and profitability.
See More
Vertex and Eli Lilly Compete in Non-Opioid Pain Management Market
- Intensifying Market Competition: Vertex Pharmaceuticals leads the non-opioid pain management market with its FDA-approved Journavx, the first oral non-opioid pain signal inhibitor, which, despite currently low revenue, is expected to see significant sales growth in the coming years and may expand into diabetic peripheral neuropathy (DPN) treatment.
- Acquisition Strategy: Eli Lilly is actively entering the non-opioid pain management space through acquisitions, including SiteOne Therapeutics for up to $1 billion and 4E Therapeutics, whose lead asset 4ET1103 demonstrated a robust safety profile in phase 1 studies, indicating Lilly's potential in this market.
- Vast Market Opportunity: Vertex estimates that there are 80 million patients suffering from acute pain in North America and Europe, with several million more in niche markets like DPN, providing significant market opportunities for both Vertex and Eli Lilly; while Vertex currently holds the lead, Lilly could dominate if its products demonstrate superior efficacy.
- Strong Financial Performance: Although Vertex has lagged broader equities over the past 12 months, its dominance in the cystic fibrosis market ensures solid financial results, with expectations of at least $500 million in revenue this year from Journavx and gene editing drug Casgevy, highlighting the company's potential in new product launches.
See More
Vertex and Eli Lilly's Market Competition in Pain Management
- Market Leadership: Vertex Pharmaceuticals holds a monopoly in the cystic fibrosis (CF) drug market, while Eli Lilly excels in anti-obesity medications and diabetes care, although both companies are actively seeking to reduce their reliance on their core markets.
- Non-Opioid Drug Innovation: Vertex's Journavx became the first oral non-opioid pain signal inhibitor approved by the FDA, and while it has not generated significant revenue yet, sales are expected to ramp up over the next few years, helping the company decrease its dependence on CF products.
- Acquisition Strategy: Eli Lilly acquired SiteOne Therapeutics last year for up to $1 billion, securing the key asset STC-004, a non-opioid treatment for chronic pain, and recently announced the acquisition of 4E Therapeutics, further expanding its footprint in the non-opioid pain treatment space.
- Market Opportunity: Vertex estimates that there are 80 million patients suffering from acute pain in North America and Europe, providing both Vertex and Eli Lilly with significant profit potential in this market; despite Vertex's first-mover advantage, Eli Lilly could still dominate if its candidates demonstrate superior efficacy.
See More
ARK Invest Increases Stake in Tesla and Snowflake While Reducing Roku Holdings
- Increased Tesla Holdings: On June 18, ARK Invest acquired approximately 44,000 shares of Tesla valued at about $17.6 million, reflecting ongoing confidence in the electric vehicle market despite market fluctuations.
- Acquisition of Snowflake: The firm also purchased around 149,700 shares of Snowflake for approximately $34.8 million, indicating a bullish outlook on cloud computing and data analytics, aiming to capitalize on future growth opportunities.
- Reduced Roku Exposure: ARK Invest sold about 561,800 shares of Roku valued at approximately $77.6 million, reducing its investment in the streaming platform, which reflects a reassessment of technology stocks and portfolio adjustments.
- Healthcare Investment: Additionally, ARK increased its stake in Eli Lilly by nearly 2,400 shares worth about $2.7 million, demonstrating a focus on the healthcare sector to diversify its portfolio amid market uncertainties.
See More
Eli Lilly Continues Growth, Surpasses $1 Trillion Market Value
- Weight Loss Market Potential: Eli Lilly's weight loss drugs, Zepbound and oral GLP-1 medication Foundayo, are experiencing rapid sales growth, particularly after Foundayo's approval for chronic weight management, with 80% of prescriptions coming from new GLP-1 users, indicating significant market potential and likely enhancing the company's leadership in this sector.
- Pipeline Diversification Investment: Eli Lilly is investing billions through acquisitions and licensing agreements to diversify its product lineup, particularly in oncology and neuroscience, with the acquisition of Morphic Holdings' MORF-057 oral medication for inflammatory bowel diseases poised to capture a significant market share, thereby reducing reliance on diabetes and obesity drugs.
- Dividend Growth Appeal: Although Eli Lilly's dividend yield is around 0.6%, the company has achieved a remarkable 239% increase in dividends over the past decade, showcasing its potential for healthy dividend growth, which attracts income-seeking investors and enhances its investment appeal.
- Strengthening Market Leadership: Eli Lilly's strong position in the weight loss market, combined with robust pipeline investments and ongoing revenue and earnings growth, positions the company to continue leading the industry over the next decade, making it a focal point for investors.
See More
Eli Lilly's Stock Soars 40%: Key Growth Drivers
- Weight Loss Market Potential: Eli Lilly's weight loss drug Zepbound (tirzepatide) is experiencing rapid sales growth, and the newly approved oral GLP-1 medication Foundayo is attracting 80% new patients, indicating significant untapped potential in this sector, which is expected to further solidify its market leadership.
- Pipeline Diversification Investment: Eli Lilly has invested billions through acquisitions and licensing agreements to expand its product lineup across multiple therapeutic areas, including oncology and neuroscience, aiming to reduce reliance on diabetes and obesity drugs and enhance future revenue streams.
- Strong Dividend Growth: Although Eli Lilly's dividend yield is around 0.6%, the company has seen a 239% increase in dividends over the past decade, showcasing its potential for healthy dividend growth, which appeals to income-seeking investors.
- Market Value Milestone: Eli Lilly has become the first healthcare company to reach a market value of $1 trillion, with a 40% stock price increase over the past 12 months, reflecting its strong performance among peers and confidence in future growth.
See More
Vertex and Eli Lilly's Market Competition in Pain Management
- Vertex Drug Approval: Vertex Pharmaceuticals' Journavx has become the first FDA-approved non-opioid pain signal inhibitor, marking a significant breakthrough in acute pain management, with expected sales growth over the coming years that will help reduce reliance on cystic fibrosis drugs.
- Eli Lilly Acquisitions: Last year, Eli Lilly acquired SiteOne Therapeutics for up to $1 billion, gaining the non-opioid chronic pain treatment STC-004, and recently announced the acquisition of 4E Therapeutics, further enhancing its competitive position in the pain management market.
- Market Potential: Vertex estimates that there are 80 million acute pain patients in North America and Europe, providing both Vertex and Eli Lilly opportunities to profit in this market; although Vertex currently leads, Eli Lilly's R&D progress could shift the competitive landscape.
- Strong Financial Performance: Despite Vertex's underperformance over the past 12 months, it expects to generate at least $500 million in revenue this year from Journavx and gene-editing drug Casgevy, indicating potential in new drug launches, while Eli Lilly is also viewed as a strong investment due to its robust pipeline and profitability.
See More
Vertex and Eli Lilly Compete in Non-Opioid Pain Management Market
- Intensifying Market Competition: Vertex Pharmaceuticals leads the non-opioid pain management market with its FDA-approved Journavx, the first oral non-opioid pain signal inhibitor, which, despite currently low revenue, is expected to see significant sales growth in the coming years and may expand into diabetic peripheral neuropathy (DPN) treatment.
- Acquisition Strategy: Eli Lilly is actively entering the non-opioid pain management space through acquisitions, including SiteOne Therapeutics for up to $1 billion and 4E Therapeutics, whose lead asset 4ET1103 demonstrated a robust safety profile in phase 1 studies, indicating Lilly's potential in this market.
- Vast Market Opportunity: Vertex estimates that there are 80 million patients suffering from acute pain in North America and Europe, with several million more in niche markets like DPN, providing significant market opportunities for both Vertex and Eli Lilly; while Vertex currently holds the lead, Lilly could dominate if its products demonstrate superior efficacy.
- Strong Financial Performance: Although Vertex has lagged broader equities over the past 12 months, its dominance in the cystic fibrosis market ensures solid financial results, with expectations of at least $500 million in revenue this year from Journavx and gene editing drug Casgevy, highlighting the company's potential in new product launches.
See More
Vertex and Eli Lilly's Market Competition in Pain Management
- Market Leadership: Vertex Pharmaceuticals holds a monopoly in the cystic fibrosis (CF) drug market, while Eli Lilly excels in anti-obesity medications and diabetes care, although both companies are actively seeking to reduce their reliance on their core markets.
- Non-Opioid Drug Innovation: Vertex's Journavx became the first oral non-opioid pain signal inhibitor approved by the FDA, and while it has not generated significant revenue yet, sales are expected to ramp up over the next few years, helping the company decrease its dependence on CF products.
- Acquisition Strategy: Eli Lilly acquired SiteOne Therapeutics last year for up to $1 billion, securing the key asset STC-004, a non-opioid treatment for chronic pain, and recently announced the acquisition of 4E Therapeutics, further expanding its footprint in the non-opioid pain treatment space.
- Market Opportunity: Vertex estimates that there are 80 million patients suffering from acute pain in North America and Europe, providing both Vertex and Eli Lilly with significant profit potential in this market; despite Vertex's first-mover advantage, Eli Lilly could still dominate if its candidates demonstrate superior efficacy.
See More
ARK Invest Increases Stake in Tesla and Snowflake While Reducing Roku Holdings
- Increased Tesla Holdings: On June 18, ARK Invest acquired approximately 44,000 shares of Tesla valued at about $17.6 million, reflecting ongoing confidence in the electric vehicle market despite market fluctuations.
- Acquisition of Snowflake: The firm also purchased around 149,700 shares of Snowflake for approximately $34.8 million, indicating a bullish outlook on cloud computing and data analytics, aiming to capitalize on future growth opportunities.
- Reduced Roku Exposure: ARK Invest sold about 561,800 shares of Roku valued at approximately $77.6 million, reducing its investment in the streaming platform, which reflects a reassessment of technology stocks and portfolio adjustments.
- Healthcare Investment: Additionally, ARK increased its stake in Eli Lilly by nearly 2,400 shares worth about $2.7 million, demonstrating a focus on the healthcare sector to diversify its portfolio amid market uncertainties.
See More
